Radiopharmaceutical Clinical Trials: Driving Innovation in Oncology Drug Development

Join IQVIA’s experts for an in-depth look into optimizing radiopharmaceutical trials—from aligning with the U.S. Food and Drug Administration’s (FDA’s) latest guidance on dosage optimization to ensuring radiation therapy quality assurance and overcoming logistical hurdles. Learn how IQVIA’s proven expertise and global capabilities can help accelerate your oncology pipeline and bring novel therapeutic modalities to market faster.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/trial-workflows

Event overview:

Radiopharmaceuticals are transforming the oncology landscape, offering new pathways for precision treatment and improved patient outcomes. Yet, designing and executing clinical trials for these complex therapies requires navigating unique regulatory, operational, and quality assurance challenges.

Join IQVIA’s experts for an in-depth look into optimizing radiopharmaceutical trials—from aligning with the U.S. Food and Drug Administration’s (FDA’s) latest guidance on dosage optimization to ensuring radiation therapy quality assurance and overcoming logistical hurdles. Learn how IQVIA’s proven expertise and global capabilities can help accelerate your oncology pipeline and bring novel therapeutic modalities to market faster.

Three key take-aways

• Gain actionable insights on regulatory trends and trial optimization.
  
• Learn how to mitigate operational risks in radiopharmaceutical studies.
  
• Understand how IQVIA’s expertise accelerates oncology innovation.

Speakers:

David Alsadius, MD, PhD
Senior Medical Director, Solid Tumor Lead, Hematology-Oncology Center of Excellence
IQVIA

David Alsadius, MD, PhD, is senior medical director for the IQVIA Oncology Center of Excellence and is a board-certified clinical oncologist with over 20 years of oncology experience. In his current role, Alsadius advises pharmaceutical and biotechnology companies on the development of oncology products, with a focus on breast cancer and gynaecologic malignancies.

Michael Armstrong, MD, PhD
Senior Director, Medical, Hematology-Oncology Center of Excellence
IQVIA Biotech

Michael Armstrong, MD, PhD, is a pediatric hematologist-oncologist with a special interest in basic science and translational research in neuroblastoma. As a member of the Hematology-Oncology Center of Excellence, he works closely with biotech companies to assist with new drug development and the administration of clinical trials with an emphasis on immuno-oncology and pediatric indications.

Michael Brave, MD
Vice President, Therapeutic and Regulatory Strategy
IQVIA

Michael Brave, MD, is the therapeutic and regulatory strategy lead at IQVIA, bringing over 30 years of combined clinical and regulatory experience as a medical oncologist. In this role, he draws on his deep clinical insight and regulatory expertise to guide therapeutic development strategies and support innovation in oncology research.

Carsten Henke
Client Partner
IQVIA

Carsten Henke is a client partner, advising emerging biopharma clients with global or local headquarters in Europe. Supporting and coordinating all client requests with a focus on commercial, he is a key contact and trusted advisor for all commercial topics. Henke’s experience spans over 30 years in pharma and biotech in both commercial and cross-functional roles; this includes leading global and European regional launch teams.

Amanda Potocky
Director of Clinical Project Management
IQVIA Biotech

Amanda L Potocky is a director of clinical project management with IQVIA, working in clinical research since 2000 and leading global cross‑functional teams across Phases 1–3. Her therapeutic portfolio spans oncology and hematology—including advanced solid tumors, non‑small cell lung cancer, leukemia, lymphoma, breast, and ovarian cancers—with roles ranging from global clinical project manager to program director, overseeing multi‑study portfolios.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/radiopharmaceutical